US-Israel health partnership funds biotech innovation—but who pays?
H.R. 4473 — BIRD Health Act of 2025 · Filed by Randy Weber (R-TX) · 8 cosponsors · Introduced Jul 16, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill establishes a formal US-Israel bilateral research program called the BIRD Health Program, administered by the existing BIRD Foundation, to jointly develop and commercialize healthcare technologies including medical devices, pharmaceuticals, diagnostics, and digital health solutions. The program authorizes $10 million per year from 2026–2032, with joint governance by the US Department of Health and Human Services and Israel's Ministry of Health, and requires annual reporting to Congress on funded projects and their economic impact.
Why we flagged it
The bill's core function is establishing a formal bilateral research and commercialization program between the US and Israel in healthcare technologies. It is neither deregulation nor a tax provision, but rather a structured international collaboration framework with dedicated funding.
What the text implies
- The bill prioritizes 'commercialization and deployment' and 'commercial potential' as selection criteria, but does not mandate that resulting treatments be affordable, accessible, or available to US patients at reasonable cost—only that they be developed and sold.
- Joint governance with Israel's Ministry of Health and administration through the BIRD Foundation (a private entity) may create opacity around how US taxpayer funds are allocated and whether projects prioritize US public health needs or bilateral economic interests.
The full analysis lists 4 implications of this text.
Who stands to gain
pharmaceutical companies; biotechnology firms; medical device manufacturers